Retrospective Observational Study of the Safety and Toxicity Management of Abemaciclib in Combination with Adjuvant Hormone Therapy in Patients with RH+ ,HER2-nonoveramplified Breast Cancer, Real-life Data (MONARCHE29)

计划入组 30 人 · 首次发布于 2024 年 10 月 1 日

A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer

计划入组 237 人 · 首次发布于 2016 年 2 月 5 日

Monarch Robotic Bronchoscopy for Lung Nodule ICG Dye Marking Before VATS

计划入组 50 人 · 首次发布于 2025 年 9 月 17 日

Monarch Casino & Resort, Inc.

United States

UNIVERSITA' POLITECNICA DELLE MARCHE

Italy

AZIENDA OSPEDALIERO-UNIVERSITARIA DELLE MARCHE

Italy

Landmark Breast Cancer Trials Reshape Treatment Paradigms for HR-positive, HER2-negative Disease

Lilly's Verzenio Demonstrates Significant Overall Survival Benefit in High-Risk Early Breast Cancer

CDK4/6 Inhibitors Show Potential in HR+/HER2- Early Breast Cancer Adjuvant Therapy